Express delivery and free returns within 21 days

Tuesday, July 5, 2022



Contact us 561.316.3330

Richard Lizzio, a Seasoned Hospital Executive, Appointed New Executive Manager of GenesisCare

Richard Lizzio joins GenesisCare with 20 years of experience across hospitals and healthcare, having held senior operational and leadership roles within St Vincent’s Health Australia, Uniting Care, Healthscope and Ramsay Health Care.

Richard Lizzio joins at an exciting time of rapid growth and expansion for GenesisCare in Australia. GenesisCare has been implementing a national integrated cancer care program to combat disrupted care pathways caused by COVID-19. GenesisCare recently opened three new world-class integrated cancer centres in areas of high unmet need and acquired the largest medical oncology provider in South Australia, Adelaide Oncology & Haematology.

GenesisCare’s Global Chief Operating Officer, Michael O’Sullivan, said: “We’re delighted to welcome Richard as GenesisCare’s new Oncology Australia Executive Manager. Richard has a wealth of experience in healthcare, and an impressive track record of re-imagining next-generation business models to achieve the best possible outcomes for patients. He will play a key role as we enter an exciting new stage of growth and development in our business.”

Richard began his career in healthcare at Ramsay Health Care, working for eight years in various hospital CEO positions in Queensland, later joining Healthscope to manage nine of its private hospitals. Since then, Richard has held several leadership roles at UnitingCare Queensland, Icon Group, and St Vincent’s Health Australia.

Newly appointed Executive Manager for Oncology Australia, Richard Lizzio, said: “I have had the great pleasure of working closely with GenesisCare’s clinicians and executive team in my previous roles and have seen first-hand the innovative, world-class care they provide to cancer patients.

“I am truly excited by the opportunity this role brings. I look forward to leading GenesisCare’s Australian business as we scale our integrated cancer care program, expand our medical oncology and theranostics portfolio, and embark on new partnerships with other leading healthcare providers.

“GenesisCare’s continued growth and investment in new centres, technology, and partnerships is founded on the company’s core belief that patients should have access to great care that achieves the best possible outcomes, close to home,” said Mr Lizzio.

In his new role, Richard will guide the expansion of GenesisCare’s integrated cancer treatment centres across Australia and will drive several new hospital partnerships. In the past six months, GenesisCare has opened three new integrated centres – GenesisCare North Shore (NSW), GenesisCare Maitland (NSW), and GenesisCare Murdoch (WA) – with Norwest Sydney (NSW) currently nearing completion.

Over the next two years, GenesisCare has a strong pipeline of new centre openings including Campbelltown (NSW), Frenches Forest (NSW) and two centres in Adelaide (SA).

Mr. Lizzio will also work in close partnership with GenesisCare’s new Chief Medical Officer, Dr Marie Burke, OAM. Dr Burke is a highly regarded radiation oncologist with more than 30 years’ experience, including a decade at GenesisCare. She was recognised for her service to medicine and the community in the 2022 Australia Day Honours list.

Spokespeople available:

  1. Richard Lizzio, Executive Manager for Oncology Australia, GenesisCare
  2. Michael O’Sullivan, Global Chief Operating Officer, GenesisCare
Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Must Read

Dr. Reddy’s Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

Under the terms of the agreement, Dr. Reddy’s acquired the Eton Pharma portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.

FUJIFILM Irvine Scientific Acquires Exclusive License for Artificial Intelligence for IVF

FUJIFILM Irvine Scientific plans to offer non-exclusive licensing of the technology to companies wishing to advance the use of AI and image-based tools in reproductive healthcare and will immediately be seeking agreements, globally.

ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions

The acquisition of MEDIFOX DAN builds on ResMed’s existing business in Germany as a leading provider of innovative cloud-connected medical devices that transform care for patients with sleep apnea and other respiratory conditions.

By using this website you agree to accept Medical Device News Magazine Privacy Policy